# US 2013/0281698 A1 · Novel 6-Amino-Morphinan Derivatives, Method of Manufacturing Them and Their Application as Analgesics

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0281698 A1
- Document ID: US20130281698A1
- Status: Published application
- Kind: A1
- Application number: 13/648,033
- Filed: 2012-10-09
- Published: 2013-10-24
- Earliest claimed: 2005-09-12
- Assignees: Alcasynn Pharmaceuticals GmbH
- Inventors: Johannes SCHUETZ; Peter KAYATZ
- Web page: https://patentgrep.com/patent/US20130281698A1

## CPC

- C07D 489/08: Oxygen atom
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/06: Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
- A61P 1/10: Laxatives
- A61P 1/12: Antidiarrhoeals
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 7/10: Antioedematous agents; Diuretics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/12: of the kidneys
- A61P 15/08: for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 23/00: Anaesthetics
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/06: Antimigraine agents
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/30: for treating abuse or dependence
- A61P 25/36: Opioid-abuse
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention provides novel 6-amino-morphinan derivatives, methods of making same, and methods of using same for analgesic purposes. The derivatives of this invention are represented by the following formula:

## Claims

### Claim 1

Compounds of formula (I),
in which the substituents have the following meaning:
R1 is hydrogen; C1-C30, preferably C1-C12, more preferably C1-C6-alkyl; C2-C30, preferably C2-C12, more preferably C2-C6-alkenyl; C2-C30, preferably C2-C12, more preferably C2-C6-alkynyl; C1-C30, preferably C1-C12, more preferably C1-C6-monohydroxyalkyl; C2-C30, preferably C2-C12, more preferably C2-C6-dihydroxyalkyl; C3-C30, preferably C3-C12, more preferably C3-C6-trihydroxyalkyl; C4-C30, preferably C4-C16-cycloalkylalkyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkyl preferably is C1-C6-alkyl; C5-C30, preferably C5-C16-cycloalkylalkenyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkenyl preferably is C2-C6-alkenyl; C5-C30, preferably C5-C16-cycloalkylalkynyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkynyl preferably is C2-C6-alkynyl; C7-C30, preferably C7-C16-arylalkyl, where aryl preferably is C6-C10-aryl and alkyl preferably is C1-C6-alkyl; C8-C30, preferably C8-C16-arylalkenyl, where aryl preferably is C6-C10-aryl and alkenyl preferably is C2-C6-alkenyl; C8-C30, preferably C8-C16-arylalkynyl, where aryl preferably is C6-C10-aryl and alkynyl preferably is C2-C6-alkynyl;
the nitrogen joined with R1 can also be quarternised by two substituents R1, which can be the same or different and which are defined as previously shown, and whereby the second, quarternised substituent can additionally have the meaning hydroxyl, oxyl (N-oxide) as well as alkoxyl;
R2, subject to the following definition of X, is hydrogen; C1-C30, preferably C1-C12, more preferably C1-C6-alkyl; C1-C30, preferably C1-C12, more preferably C1-C6-monohydroxyalkyl; C2-C30, preferably C2-C12, more preferably C2-C6-dihydroxyalkyl; C3-C30, preferably C3-C12, more preferably C3-C6-trihydroxyalkyl; C2-C30, preferably C2-C12, more preferably C2-C6-alkenyl; C2-C30, preferably C2-C12, more preferably C2-C6-alkynyl; C4-C30, preferably C4-C16-cycloalkylalkyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkyl preferably is C1-C6-alkyl; C5-C30, preferably C5-C16-cycloalkylalkenyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkenyl preferably is C2-C6-alkenyl; C5-C30, preferably C5-C16-cycloalkylalkynyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkynyl preferably is C2-C6-alkynyl; C7-C30, preferably C7-C16-arylalkyl, where aryl preferably is C6-C10-aryl and alkyl preferably is C1-C6-alkyl; C8-C30, preferably C8-C16-arylalkenyl, where aryl preferably is C6-C10-aryl and alkenyl preferably is C2-C6-alkenyl; C8-C30, preferably C8-C16-arylalkynyl, where aryl preferably is C6-C10-aryl and alkynyl preferably is C2-C6-alkynyl; C2-C30, preferably C2-C12, more preferably C2-C6-alkanoyl; C3-C30, preferably C3-C12, more preferably C3-C6-alkenoyl; C3-C30, preferably C3-C12, more preferably C3-C6-alkinoyl; C7-C30, preferably C7-C16-arylalkanoyl, where aryl preferably is C6-C10-aryl and alkanoyl preferably is C1-C6-alkanoyl; C9-C30, preferably C9-C16-arylalkenoyl, where aryl preferably is C6-C10-aryl and alkenoyl preferably is C3-C6-alkenoyl; C9-C30, preferably C9-C16-arylalkinoyl, where aryl preferably is C6-C10-aryl and alkinoyl preferably is C3-C6-alkinoyl;
R3 is hydrogen; C1-C30, preferably C1-C12, more preferably C1-C6-alkyl; C2-C30, preferably C2-C12, more preferably C2-C6-alkenyl; C7-C30, preferably C7-C16-arylalkyl, where aryl preferably is C6-C10-aryl and alkyl preferably is C1-C6-alkyl; C8-C30, preferably C8-C16-arylalkenyl, where aryl preferably is C6-C10-aryl and alkenyl preferably is C2-C6-alkenyl; alkoxyalkyl, where alkoxy is C1-C6-alkoxy and alkyl is C1-C6-alkyl; CO2(C1-C6-alkyl); CO2H; CH2OH;
R4, subject to the definition of Y, is hydrogen; C1-C30, preferably C1-C12, more preferably C1-C6-alkyl; C2-C30, preferably C2-C12, more preferably C2-C6-alkenyl; C2-C30, preferably C2-C12, more preferably C2-C6-alkynyl; C4-C30, preferably C4-C16-cycloalkylalkyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkyl preferably is C1-C6-alkyl; C5-C30, preferably C5-C16-cycloalkylalkenyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkenyl preferably is C2-C6-alkenyl; C5-C30, preferably C5-C16-cycloalkylalkynyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkynyl preferably is C2-C6-alkynyl; C7-C30, preferably C7-C16-arylalkyl, where aryl preferably is C6-C10-aryl and alkyl preferably is C1-C6-alkyl; C8-C30, preferably C8-C16-arylalkenyl, where aryl preferably is C6-C10-aryl and alkenyl preferably is C2-C6-alkenyl; C8-C30, preferably C8-C16-arylalkynyl, where aryl preferably is C6-C10-aryl and alkynyl preferably is C2-C6-alkynyl; C2-C30, preferably C2-C12, more preferably C2-C6-alkanoyl; C3-C30, preferably C3-C12, more preferably C3-C6-alkenoyl; C3-C30, preferably C3-C12, more preferably C3-C6-alkinoyl; C7-C30, preferably C7-C16-arylalkanoyl, where aryl preferably is C6-C10-aryl and alkanoyl preferably is C1-C6-alkanoyl; C9-C30, preferably C9-C16-arylalkenoyl, where aryl preferably is C6-C10-aryl and alkenoyl preferably is C3-C6-alkenoyl; C9-C30, preferably C9-C16-arylalkinoyl, where aryl preferably is C6-C10-aryl and alkinoyl preferably is C3-C6-alkinoyl; iminomethyl, formamidinyl, C1-C30, preferably C1-C12, more preferably C1-C6—N-alkyl- and N,N′-dialkylformamidinyl; C2-C30, preferably C2-C12, more preferably C2-C6—N-alkenyl- and N,N′-dialkenylformamidinyl; C2-C30, preferably C2-C12, more preferably C2-C6—N-alkynyl- and N,N′-dialkynylformamidinyl; C4-C30, preferably C4-C16—N-cycloalkylalkyl- and N,N′-dicycloalkylalkylformamidinyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkyl preferably is C1-C6-alkyl; C5-C30, preferably C5-C16—N-cylcoalkylalkenyl- and N,N′-dicycloalkylalkenylformamidinyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkenyl preferably is C2-C6-alkenyl; C5-C30, preferably C5-C16—N-cycloalkylalkynyl- and N,N′-dicycloalkylalkynylformamidinyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkynyl preferably is C2-C6-alkynyl; C7-C30, preferably C7-C16—N-arylalkyl- and N,N′-diarylalkylformamidinyl, where aryl preferably is C6-C10-aryl and alkyl preferably is C1-C6-alkyl;
R5 and R6, which can be the same or different, are selected from hydrogen; C1-C30, preferably C1-C12, more preferably C1-C6-alkyl; C2-C30, preferably C2-C12, more preferably C2-C6-alkenyl; C2-C30, preferably C2-C12, more preferably C2-C6-alkynyl; C4-C30, preferably C4-C16-cycloalkylalkyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkyl preferably is C1-C6-alkyl; C5-C30, preferably C5-C16-cycloalkylalkenyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkenyl preferably is C2-C6-alkenyl; C5-C30, preferably C5-C16-cycloalkylalkynyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkynyl preferably is C2-C6-alkynyl; C7-C30, preferably C7-C16-arylalkyl, where aryl preferably is C6-C10-aryl and alkyl preferably is C1-C6-alkyl; C8-C30, preferably C8-C16-arylalkenyl, where aryl preferably is C6-C10-aryl and alkenyl preferably is C2-C6-alkenyl; C8-C30, preferably C8-C16-arylalkynyl, where aryl preferably is C6-C10-aryl and alkynyl preferably is C2-C6-alkynyl; furthermore, CH(A′)CO2B, where A′ is hydrogen; hydroxyl; C1-C30, preferably C1-C12, more preferably C1-C6-alkyl; C2-C30, preferably C2-C12, more preferably C2-C6-alkenyl; C2-C30, preferably C2-C12, more preferably C2-C6-alkynyl; C4-C30, preferably C4-C16-cycloalkylalkyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkyl preferably is C1-C6-alkyl; C5-C30, preferably C5-C16-cycloalkylalkenyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkenyl preferably is C2-C6-alkenyl; C5-C30, preferably C5-C16-cycloalkylalkynyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkynyl preferably is C2-C6-alkynyl; C7-C30, preferably C7-C16-arylalkyl, where aryl preferably is C6-C10-aryl and alkyl preferably is C1-C6-alkyl; C8-C30, preferably C8-C16-arylalkenyl, where aryl preferably is C6-C10-aryl and alkenyl preferably is C2-C6-alkenyl; C8-C30, preferably C8-C16-arylalkynyl, where aryl preferably is C6-C10-aryl and alkynyl preferably is C2-C6-alkynyl; amino; C1-C30, preferably C1-C12, more preferably C1-C6-alkylamino; guanidino; C1-C30, preferably C1-C12, more preferably C1-C6-alkyl-CO2B; and where B is hydrogen; C1-C30-, preferably C1-C12, more preferably C1-C6-alkyl; C2-C30-, preferably C2-C12, more preferably C2-C6-alkenyl; C2-C30-, preferably C2-C12, more preferably C2-C6-alkynyl; C4-C30, preferably C4-C16-cycloalkylalkyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkyl preferably is C1-C6-alkyl; C5-C30, preferably C5-C16-cycloalkylalkenyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkenyl preferably is C2-C6-alkenyl; C5-C30, preferably C5-C16-cycloalkylalkynyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkynyl preferably is C2-C6-alkynyl; C7-C30, preferably C7-C16-arylalkyl, where aryl preferably is C6-C10-aryl and alkyl preferably is C1-C6-alkyl; C8-C30, preferably C8-C16-arylalkenyl, where aryl preferably is C6-C10-aryl and alkenyl preferably is C2-C6-alkenyl; C8-C30, preferably C8-C16-arylalkynyl, where aryl preferably is C6-C10-aryl and alkynyl preferably is C2-C6-alkynyl; phenyl; substituted phenyl; CH2OCO—C1-C6-alkyl; CH(C1-C6-alkyl)OCO—C1-C6-alkyl; CH2OCOO—C1-C6-alkyl; CH(C1-C6-alkyl)OCO—C1-C6-alkyl; CH2CON(C1-C6-alkyl)2; CH(C1-C6-alkyl)CON(C1-C6-alkyl)2; phthalidyl, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl, furthermore CH(A)SO3B, whereby A and B are defined as above; also iminomethyl, formamidinyl, C1-C30, preferably C1-C12, more preferably C1-C6—N-alkyl- and N,N′-dialkylformamidinyl; C2-C30, preferably C2-C12, more preferably C2-C6—N-alkenyl- and N,N′-dialkenylformamidinyl; C2-C30, preferably C2-C12, more preferably C2-C6—N-alkynyl- and N,N′-dialkynylformamidinyl; C4-C30, preferably C4-C16—N-cycloalkylalkyl- and N,N′-dicycloalkylalkylformamidinyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkyl preferably is C1-C6-alkyl; C5-C30, preferably C5-C16—N-cylcoalkylalkenyl- and N,N′-dicycloalkylalkenylformamidinyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkenyl preferably is C2-C6-alkenyl; C5-C30, preferably C5-C16—N-cycloalkylalkynyl- and N,N′-dicycloalkylalkynylformamidinyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkynyl preferably is C2-C6-alkynyl; C7-C30, preferably C7-C16—N-arylalkyl- and N,N′-diarylalkylformamidinyl, where aryl preferably is C6-C10-aryl and alkyl preferably is C1-C6-alkyl; C8-C30, preferably C8-C16—N-arylalkenyl- and N,N′-diarylalkenylformamidinyl, where aryl preferably is C6-C10-aryl and alkenyl preferably is C2-C6-alkenyl; C8-C30, preferably C8-C16—N-arylalkynyl- and N,N′-diarylalkynylformamidinyl, where aryl preferably is C6-C10-aryl and alkynyl preferably is C2-C6-alkynyl; C2-C30, preferably C2-C12, more preferably C2-C7—N-alkyloxycarbonyl- and N,N′-bis(alkyloxycarbonyl)formamidinyl; C3-C30, preferably C3-C12, more preferably C3-C8—N-alkenyloxycarbonyl- and N,N′-bis(alkenyloxycarbonyl)formamidinyl; C3-C30, preferably C3-C12, more preferably C3-C8—N-alkynyloxycarbonyl- and N,N′-bis(alkynyloxycarbonyl)formamidinyl; C8-C30, preferably C8-C17—N-arylalkyloxycarbonyl- and N,N′-bis(arylalkyloxycarbonyl)formamidinyl, where aryl preferably is C6-C10-aryl and alkyloxy preferably is C1-C6-alkyloxy; C9-C30, preferably C9-C17—N-arylalkenyloxycarbonyl- and N,N′-bis(arylalkenyloxycarbonyl)formamidinyl, where aryl preferably is C6-C10-aryl and alkenyloxy preferably is C2-C6-alkenyloxy; C9-C30, preferably C9-C17—N-arylalkynyloxycarbonyl- and N,N′-bis(arylalkynyloxycarbonyl)formamidinyl, where aryl preferably is C6-C10-aryl and alkynyloxy preferably is C2-C6-alkynyloxy; C1-C30, preferably C1-C12, more preferably C1-C6—N-alkanoyl- and N,N′-dialkanoylformamidinyl; C3-C30, preferably C3-C12, more preferably C3-C6—N-alkenoyl- and N,N′-dialkenoylformamidinyl; C3-C30, preferably C3-C12, more preferably C3-C6—N-alkinoyl- and N,N′-dialkinoylformamidinyl; C7-C30, preferably C7-C16—N-arylalkanoyl- and N,N′-diarylalkanoylformamidinyl, where aryl preferably is C6-C10-aryl and alkanoyl preferably is C1-C6-alkyl; C9-C30, preferably C9-C16—N-arylalkenoyl- and N,N′-diarylalkenoylformamidinyl, where aryl preferably is C6-C10-aryl and alkenoyl preferably is C3-C6-alkenoyl; C9-C30, preferably C9-C16—N-arylalkinoyl- and N,N′-diarylalkinoylformamidinyl, where aryl preferably is C6-C10-aryl and alkinoyl preferably is C3-C6-alkinoyl; 4,5-dihydro-1H-imidazol-2-yl, 1,4,5,6-tetrahydropyrimidin-2-yl, 4,5,6,7-tetrahydro-1H-[1,3]diazepin-2-yl;
and a group selected from an acid group or a derivative thereof bearing residues and moieties forming, together with the nitrogen atom to which they are bound, a residue corresponding to an amino acid, an amino acid derivative and/or a dimer or oligomer thereof and/or a peptide comprising up to 30 amino acid units, wherein at least one of R5 and R6 is selected from such a group;
X is oxygen, sulphur or methylene or the group (X—R2) is H and
Y is oxygen or the group (Y—R4) is H;
and pharmaceutically acceptable acid addition salts as well as base addition salts and easily accessible derivatives (e.g. esters or amides of amino acid derivatives), as well as polymorphic forms thereof.

### Claim 2 (depends on 1)

Compounds according to claim 1, wherein the at least one group selected from an acid group or a derivative thereof bearing residue and moieties forming, together with the nitrogen atom to which they are bound, a residue corresponding to an amino acid, an amino acid derivative and/or a dimer or oligomer thereof and/or a peptide comprising up to 30 amino acid units for R5 and R6, which can be the same or different, is selected from (C1-C30-alkyl)CO2B; (C1-C30-alkenyl)CO2B; (C1-C30-alkynyl)CO2B; (C4-C30-cycloalkylalkyl)CO2B, where cycloalkyl is C3-C10-cycloalkyl and alkyl is C1-C27-alkyl; (C4-C30-cycloalkylalkenyl)CO2B, where cycloalkyl is C3-C10-cycloalkyl and alkenyl is C2-C27-alkenyl; (C4-C30-cycloalkylalkynyl)CO2B, where cycloalkyl is C3-C10-cycloalkyl and alkynyl is C2-C27-alkynyl; (C7-C30-arylalkyl)CO2B, where aryl is C6-C10-aryl and alkyl is C1-C24-alkyl; (C8-C30-arylalkenyl)CO2B, where aryl is C6-C10-aryl and alkenyl is C2-C24-alkenyl; (C8-C30-arylalkynyl)CO2B, where aryl is C6-C10-aryl and alkynyl is C2-C24-alkynyl;
(cyclic C3-C10-alkyl)CO2B; (cyclic C3-C10-alkenyl)CO2B; (cyclic C3-C10-alkynyl)CO2B; (bicyclic C6-C20-alkyl)CO2B; (bicyclic C6-C20-alkenyl)CO2B; (bicyclic C6-C20-alkynyl)CO2B; (cyclic C3-C10-alkyl fused with C6-C10 aromatic ring system)CO2B; (cyclic C3-C10-alkenyl fused with C6-C14 aromatic ring system)CO2B; (cyclic C3-C14-alkynyl fused with C6-C10 aromatic ring system)CO2B;
[(C1-C30-alkyl)CO2B]CO2B; [(C1-C30-alkenyl)CO2B]CO2B; [(C1-C30-alkynyl)CO2B]CO2B; [(C4-C30-cycloalkylalkyl)CO2B]CO2B, where cycloalkyl is C3-C10-cycloalkyl and alkyl is C1-C27-alkyl; [(C4-C30-cycloalkylalkenyl)CO2B]CO2B, where cycloalkyl is C3-C10-cycloalkyl and alkenyl is C2-C27-alkenyl; [(C4-C30-cycloalkylalkynyl)CO2B]CO2B, where cycloalkyl is C3-C10-cycloalkyl and alkynyl is C2-C27-alkynyl; [(C7-C30-arylalkyl)CO2B]CO2B, where aryl is C6-C10-aryl and alkyl is C1-C24-alkyl; [(C7-C30-arylalkenyl)CO2B]CO2B, where aryl is C6-C10-aryl and alkenyl is C2-C24-alkenyl; [(C7-C30-arylalkynyl)CO2B]CO2B, where aryl is C6-C10-aryl and alkynyl is C2-C24-alkynyl;
[(C1-C30-alkyl)CONH2]CO2B; [(C1-C30-alkenyl)CONH2]CO2B; [(C1-C30-alkynyl)CONH2]CO2B; [(C4-C30-cycloalkylalkyl)CONH2]CO2B, where cycloalkyl is C3-C10-cycloalkyl and alkyl is C1-C27-alkyl; [(C4-C30-cycloalkylalkenyl)CONH2]CO2B, where cycloalkyl is C3-C10-cycloalkyl and alkenyl is C2-C27-alkenyl; [(C4-C30-cycloalkylalkynyl)CONH2]CO2B, where cycloalkyl is C3-C10-cycloalkyl and alkynyl is C2-C27-alkynyl; [(C7-C30-arylalkyl)CONH2]CO2B, where aryl is C6-C10-aryl and alkyl is C1-C24-alkyl; [(C7-C30-arylalkenyl)CONH2]CO2B, where aryl is C6-C10-aryl and alkenyl is C2-C24-alkenyl; [(C7-C30-arylalkynyl)CONH2]CO2B, where aryl is C6-C10-aryl and alkynyl is C2-C24-alkynyl;
(C1-C30-alkyl-S-A)CO2B; (C1-C30-alkenyl-S-A)CO2B; (C1-C30-alkynyl-S-A)CO2B; (C4-C30-cycloalkylalkyl-S-A)CO2B, where cycloalkyl is C3-C10-cycloalkyl and alkyl is C1-C27-alkyl; (C4-C30-cycloalkylalkenyl-S-A)CO2B, where cycloalkyl is C3-C10-cycloalkyl and alkenyl is C2-C27-alkenyl; (C4-C30-cycloalkylalkynyl-S-A)CO2B, where cycloalkyl is C3-C10-cycloalkyl and alkynyl is C2-C27-alkynyl; (C7-C30-arylalkyl-S-A)CO2B, where aryl is C6-C10-aryl and alkyl is C1-C24-alkyl; (C8-C30-arylalkenyl-S-A)CO2B, where aryl is C6-C10-aryl and alkenyl is C2-C24-alkenyl; (C8-C30-arylalkynyl-S-A)CO2B, where aryl is C6-C10-aryl and alkynyl is C2-C24-alkynyl; A is H; C1-C30-alkyl; C1-C30-alkenyl; C1-C30-alkynyl; C4-C30-cycloalkylalkyl, where cycloalkyl is C3-C10-cycloalkyl and alkyl is C1-C27-alkyl; C4-C30-cycloalkylalkenyl, where cycloalkyl is C3-C10-cycloalkyl and alkenyl is C2-C27-alkenyl; C4-C30-cycloalkylalkynyl, where cycloalkyl is C3-C10-cycloalkyl and alkynyl is C2-C27-alkynyl; C7-C30-arylalkyl, where aryl is C6-C10-aryl and alkyl is C1-C24-alkyl; C8-C30-arylalkenyl, where aryl is C6-C10-aryl and alkenyl is C2-C24-alkenyl; C8-C30-arylalkynyl, where aryl is C6-C10-aryl and alkynyl is C2-C24-alkynyl; or A is selected from (C1-C30-alkyl-S-a)CO2B; (C1-C30-alkenyl-S-a)CO2B; (C1-C30-alkynyl-S-a)CO2B; (C4-C30-cycloalkylalkyl-S-a)CO2B, where cycloalkyl is C3-C10-cycloalkyl and alkyl is C1-C27-alkyl; (C4-C30-cycloalkylalkenyl-S-a)CO2B, where cycloalkyl is C3-C10-cycloalkyl and alkenyl is C2-C27-alkenyl; (C4-C30-cycloalkylalkynyl-S-a)CO2B, where cycloalkyl is C3-C10-cycloalkyl and alkynyl is C2-C27-alkynyl; (C7-C30-arylalkyl-S-a)CO2B, where aryl is C6-C10-aryl and alkyl is C1-C24-alkyl; (C8-C30-arylalkenyl-S-a)CO2B, where aryl is C6-C10-aryl and alkenyl is C2-C24-alkenyl; (C8-C30-arylalkynyl-S-a)CO2B, where aryl is C6-C10-aryl and alkynyl is C2-C24-alkynyl; wherein a designates the connecting bond;
(CHDCONH)nCHDCO2B, where n is from 1 to 30, where D is H; C1-C30-alkyl; C1-C30-alkenyl; C1-C30-alkynyl; C4-C30-cycloalkylalkyl, where cycloalkyl is C3-C10-cycloalkyl and alkyl is C1-C27-alkyl; C4-C30-cycloalkylalkenyl, where cycloalkyl is C3-C10-cycloalkyl and alkenyl is C2-C27-alkenyl; C4-C30-cycloalkylalkynyl, where cycloalkyl is C3-C10-cycloalkyl and alkynyl is C2-C27-alkynyl; C7-C30-arylalkyl, where aryl is C6-C10-aryl and alkyl is C1-C24-alkyl; C8-C30-arylalkenyl, where aryl is C6-C10-aryl and alkenyl is C2-C24-alkenyl; C8-C30-arylalkynyl, where aryl is C6-C10-aryl and alkynyl is C2-C24-alkynyl; (C1-C30-alkyl)CO2B; (C1-C30-alkenyl)CO2B; (C1-C30-alkynyl)CO2B; (C4-C30-cycloalkylalkyl)CO2B, where cycloalkyl is C3-C10-cycloalkyl and alkyl is C1-C27-alkyl; (C4-C30-cycloalkylalkenyl)CO2B, where cycloalkyl is C3-C10-cycloalkyl and alkenyl is C2-C27-alkenyl; (C4-C30-cycloalkylalkynyl)CO2B, where cycloalkyl is C3-C10-cycloalkyl and alkynyl is C2-C27-alkynyl; (C7-C30-arylalkyl)CO2B, where aryl is C6-C10-aryl and alkyl is C1-C24-alkyl; (C7-C30-arylalkenyl)CO2B, where aryl is C6-C10-aryl and alkenyl is C2-C24-alkenyl; (C7-C30-arylalkynyl)CO2B, where aryl is C6-C10-aryl and alkynyl is C2-C24-alkynyl;
(C1-C30-alkyl)CONH2; (C1-C30-alkenyl)CONH2; (C1-C30-alkynyl)CONH2; (C4-C30-cycloalkylalkyl)CONH2, where cycloalkyl is C3-C10-cycloalkyl and alkyl is C1-C27-alkyl; (C4-C30-cycloalkylalkenyl)CONH2, where cycloalkyl is C3-C10-cycloalkyl and alkenyl is C2-C27-alkenyl; (C4-C30-cycloalkylalkynyl)CONH2, where cycloalkyl is C3-C10-cycloalkyl and alkynyl is C2-C27-alkynyl; (C7-C30-arylalkyl)CONH2, where aryl is C6-C10-aryl and alkyl is C1-C24-alkyl; (C7-C30-arylalkenyl)CONH2, where aryl is C6-C10-aryl and alkenyl is C2-C24-alkenyl; (C7-C30-arylalkynyl)CONH2, where aryl is C6-C10-aryl and alkynyl is C2-C24-alkynyl;
wherein B is as defined in claim 1;
(C1-C30-alkyl)SO3A#; (C1-C30-alkenyl)SO3#; (C1-C30-alkynyl)SO3A#; (C4-C30-cycloalkylalkyl)SO3A#, where cycloalkyl is C3-C10-cycloalkyl and alkyl is C1-C27-alkyl; (C4-C30-cycloalkylalkenyl)SO3A#, where cycloalkyl is C3-C10-cycloalkyl and alkenyl is C2-C27-alkenyl; (C4-C30-cycloalkylalkynyl)SO3A#, where cycloalkyl is C3-C10-cycloalkyl and alkynyl is C2-C27-alkynyl; (C7-C30-arylalkyl)SO3A#, where aryl is C6-C10-aryl and alkyl is C1-C24-alkyl; (C8-C30-arylalkenyl)SO3A#, where aryl is C6-C10-aryl and alkenyl is C2-C24-alkenyl; (C8-C30-arylalkynyl)SO3A#, where aryl is C6-C10-aryl and alkynyl is C2-C24-alkynyl; (C1-C30-alkyl)PO(OA#)2; (C1-C30-alkenyl)PO(OA#)2; (C1-C30-alkynyl)PO(OA#)2; (C4-C30-cycloalkylalkyl)PO(OA#)2, where cycloalkyl is C3-C10-cycloalkyl and alkyl is C1-C27-alkyl; (C4-C30-cycloalkylalkenyl)PO(OA#)2, where cycloalkyl is C3-C10-cycloalkyl and alkenyl is C2-C27-alkenyl; (C4-C30-cycloalkylalkynyl)PO(OA#)2, where cycloalkyl is C3-C10-cycloalkyl and alkynyl is C2-C27-alkynyl; (C7-C30-arylalkyl)PO(OA#)2, where aryl is C6-C10-aryl and alkyl is C1-C24-alkyl; (C8-C30-arylalkenyl)PO(OA#)2, where aryl is C6-C10-aryl and alkenyl is C2-C24-alkenyl; (C8-C30-arylalkynyl)PO(OA#)2, where aryl is C6-C10-aryl and alkynyl is C2-C24-alkynyl; A# is H; C1-C30-alkyl; C1-C30-alkenyl; C1-C30-alkynyl; C4-C30-cycloalkylalkyl, where cycloalkyl is C3-C10-cycloalkyl and alkyl is C1-C27-alkyl; C4-C30-cycloalkylalkenyl, where cycloalkyl is C3-C10-cycloalkyl and alkenyl is C2-C27-alkenyl; C4-C30-cycloalkylalkynyl, where cycloalkyl is C3-C10-cycloalkyl and alkynyl is C2-C27-alkynyl; C7-C30-arylalkyl, where aryl is C6-C10-aryl and alkyl is C1-C24-alkyl; C8-C30-arylalkenyl, where aryl is C6-C10-aryl and alkenyl is C2-C24-alkenyl; C8-C30-arylalkynyl, where aryl is C6-C10-aryl and alkynyl is C2-C24-alkynyl.

### Claim 3 (depends on 1)

Compounds of claim 1, selected from:
(2S)-2-[(4,5α-Epoxy-3,14β-dihydroxy-17-methylmorphinan-6α-yl)amino]propionic acid tert-butyl ester
(2S)-2-[(4,5α-Epoxy-3,14β-dihydroxy-17-methylmorphinan-6β-yl)amino]propionic acid tert-butyl ester
(2S)-2-[(4,5α-Epoxy-3,14β-dihydroxy-17-methylmorphinan-6α-yl)amino]propionic acid
(2S)-2-[(4,5α-Epoxy-3,14β-dihydroxy-17-methylmorphinan-6β-yl)amino]propionic acid
(2S)-2-[(4,5α-Epoxy-3,14β-dihydroxy-17-methylmorphinan-6α-yl)amino]-3-phenylpropionic acid tert-butyl ester
(2S)-2-[(4,5α-Epoxy-3,14β-dihydroxy-17-methylmorphinan-6β-yl)amino]-3-phenylpropionic acid tert-butyl ester
(2S)-2-[(4,5α-Epoxy-3,14β-dihydroxy-17-methylmorphinan-6α-yl)amino]-3-phenylpropionic acid
(2S)-2-[(4,5α-Epoxy-3,14β-dihydroxy-17-methylmorphinan-6β-yl)amino]-3-phenylpropionic acid
3-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6α-yl)amino]propionic acid tert-butyl ester
3-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6β-yl)amino]propionic acid tert-butyl ester
3-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6α-yl)amino]propionic acid
3-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6β-yl)amino]propionic acid
4-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6α-yl)amino]butyric acid tert-butyl ester
4-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6β-yl)amino]butyric acid tert-butyl ester
4-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6α-yl)amino]butyric acid
4-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6β-yl)amino]butyric acid
(2S)-2-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6α-yl)amino]-3-methylbutyric acid tert-butyl ester
(2S)-2-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6β-yl)amino]-3-methylbutyric acid tert-butyl ester
(2S)-2-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6α-yl)amino]-3-methylbutyric acid
(2S)-2-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6β-yl)amino]-3-methylbutyric acid
(2R)-2-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6α-yl)amino]-3-methylbutyric acid tert-butyl ester
(2R)-2-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6β-yl)amino]-3-methylbutyric acid tert-butyl ester
(2R)-2-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6α-yl)amino]-3-methylbutyric acid
(2R)-2-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6β-yl)amino]-3-methylbutyric acid
(2S)-2-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6α-yl)amino]butanedioic acid di-tert-butyl ester
(2S)-2-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6β-yl)amino]butanedioic acid di-tert-butyl ester
(2S)-2-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6α-yl)amino]butanedioic acid
(2S)-2-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6β-yl)amino]butanedioic acid
(2S)-2-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6α-yl)amino]pentanedioic acid di-tert-butyl ester
(2S)-2-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6β-yl)amino]pentanedioic acid di-tert-butyl ester
(2S)-2-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6α-yl)amino]pentanedioic acid
(2S)-2-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6β-yl)amino]pentanedioic acid
(2S)-3-Carbamoyl-2-[(4,5α-epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6α-yl)amino]propionic acid tert-butyl ester
(2S)-3-Carbamoyl-2-[(4,5α-epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6β-yl)amino]propionic acid tert-butyl ester
(2S)-3-Carbamoyl-2-[(4,5α-epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6α-yl)amino]propionic acid
(2S)-3-Carbamoyl-2-[(4,5α-epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6β-yl)amino]propionic acid
(2S)-4-Carbamoyl-2-[(4,5α-epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6α-yl)amino]butyric acid tert-butyl ester
(2S)-4-Carbamoyl-2-[(4,5α-epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6β-yl)amino]butyric acid tert-butyl ester
(2S)-4-Carbamoyl-2-[(4,5α-epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6α-yl)amino]butyric acid
(2S)-4-Carbamoyl-2-[(4,5α-epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6β-yl)amino]butyric acid
(2S)-2-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6α-yl)amino]-4-methylthiobutyric acid tert-butyl ester
(2S)-2-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6β-yl)amino]-4-methylthiobutyric acid tert-butyl ester
(2S)-2-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6α-yl)amino]-4-methylthiobutyric acid
(2S)-2-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6β-yl)amino]-4-methylthiobutyric acid
(2S)-2-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6α-yl)amino]-3-(1H-indol-3-yl)propionic acid tert-butyl ester
(2S)-2-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6β-yl)amino]-3-(1H-indol-3-yl)propionic acid tert-butyl ester
(2S)-2-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6α-yl)amino]-3-(1H-indol-3-yl)propionic acid
(2S)-2-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6β-yl)amino]-3-(1H-indol-3-yl)propionic acid
(2S)-1-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6α-yl)]pyrrolidine-2-carboxylic acid tert-butyl ester
(2S)-1-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6β-yl)]pyrrolidine-2-carboxylic acid tert-butyl ester
2-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6α-yl)amino]ethane sulfonic acid
2-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6α-yl)amino]ethane sulfonic acid
2-{2-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6α-yl)amino]acetylamino}acetic acid benzyl ester
2-{2-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6 (3-yl)amino]acetylamino}acetic acid benzyl ester
2-{2-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6α-yl)amino]acetylamino}acetic acid
2-{2-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6 (3-yl)amino]acetylamino}acetic acid
(2S)-2-{[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6α-yl)amino]-(2S)-3-methylbutyrylamino}-3-(4-hydroxyphenyl)propionic acid benzyl ester
(2S)-2-{[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6β-yl)amino]-(2S)-3-methylbutyrylamino}-3-(4-hydroxyphenyl)propionic acid benzyl ester
(2S)-2-{[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6α-yl)amino]-(2S)-3-methylbutyrylamino}-3-(4-hydroxyphenyl)propionic acid
(2S)-2-{[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6β-yl)amino]-(2S)-3-methylbutyrylamino}-3-(4-hydroxyphenyl)propionic acid
(2S,3R)-2-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6α-yl)amino]-3-hydroxybutyric acid tert-butyl ester
(2S,3R)-2-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6β-yl)amino]-3-hydroxybutyric acid tert-butyl ester
(2S,3R)-2-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6α-yl)amino]-3-hydroxybutyric acid
(2S,3R)-2-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6β-yl)amino]-3-hydroxybutyric acid
(2S)-2-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6α-yl)amino]-3-hydroxypropionic acid tert-butyl ester
(2S)-2-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6β-yl)amino]-3-hydroxypropionic acid tert-butyl ester
(2S)-2-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6α-yl)amino]-3-hydroxypropionic acid
(2S)-2-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6β-yl)amino]-3-hydroxypropionic acid
(2S)-6-Benzyloxycarbonylamino-2-[(4,5α-epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6α-yl)amino]hexanoic acid tert-butyl ester
(2S)-6-Benzyloxycarbonylamino-2-[(4,5α-epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6β-yl)amino]hexanoic acid tert-butyl ester
(2S)-6-Amino-2-[(4,5α-epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6α-yl)amino]hexanoic acid
(2S)-6-Amino-2-[(4,5α-epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6β-yl)amino]hexanoic acid
(2S)-2-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6α-yl)amino]-4-methylpentanoic acid tert-butyl ester
(2S)-2-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6β-yl)amino]-4-methylpentanoic acid tert-butyl ester
(2S)-2-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6α-yl)amino]-4-methylpentanoic acid
(2S)-2-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6β-yl)amino]-4-methylpentanoic acid
(2S,3S)-2-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6α-yl)amino]-3-methylpentanoic acid tert-butyl ester
(2S,3S)-2-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6β-yl)amino]-3-methylpentanoic acid tert-butyl ester
(2S,3S)-2-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6α-yl)amino]-3-methylpentanoic acid
(2S,3S)-2-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6β-yl)amino]-3-methylpentanoic acid
3-[(17-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-methoxymorphinan-6α-yl)amino]propionic acid tert-butyl ester
3-[(17-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-methoxymorphinan-6β-yl)amino]propionic acid tert-butyl ester
3-[(17-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-methoxymorphinan-6α-yl)amino]propionic acid
3-[(17-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-methoxymorphinan-6β-yl)amino]propionic acid
4-[(17-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-methoxymorphinan-6α-yl)amino]butyric acid tert-butyl ester
3-[(17-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-methoxymorphinan-6β-yl)amino]butyric acid tert-butyl ester
3-[(17-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-methoxymorphinan-6α-yl)amino]butyric acid
3-[(17-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-methoxymorphinan-6β-yl)amino]butyric acid
(2S)-2-[(17-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-methoxymorphinan-6α-yl)amino]-3-methylbutyric acid tert-butyl ester
(2S)-2-[(17-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-methoxymorphinan-6β-yl)amino]-3-methylbutyric acid tert-butyl ester
(2S)-2-[(17-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-methoxymorphinan-6α-yl)amino]-3-methylbutyric acid
(2S)-2-[(17-Cyclopropylmethyl-4,5α-eEpoxy-3-hydroxy-14β-methoxymorphinan-6β-yl)amino]-3-methylbutyric acid
(2R)-2-[(17-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-methoxymorphinan-6α-yl)amino]-3-methylbutyric acid tert-butyl ester
(2R)-2-[(17-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-methoxymorphinan-6β-yl)amino]-3-methylbutyric acid tert-butyl ester
(2R)-2-[(17-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-methoxymorphinan-6α-yl)amino]-3-methylbutyric acid
(2R)-2-[(17-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-methoxymorphinan-6β-yl)amino]-3-methylbutyric acid
(2S)-2-[(17-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-methoxymorphinan-6α-yl)amino]butanedioic acid di-tert-butyl ester
(2S)-2-[(17-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-methoxymorphinan-6α-yl)amino]butanedioic acid di-tert-butyl ester
(2S)-2-[(17-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-methoxymorphinan-6β-yl)amino]butanedioic acid di-tert-butyl ester
(2S)-2-[(17-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-methoxymorphinan-6α-yl)amino]butanedioic acid
(2S)-2-[(17-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-methoxymorphinan-6β-yl)amino]butanedioic acid
(2S)-2-[(17-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-methoxymorphinan-6α-yl)amino]propionic acid tert-butyl ester
(2S)-2-[(17-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-methoxymorphinan-6β-yl)amino]propionic acid tert-butyl ester
(2S)-2-[(17-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-methoxymorphinan-6α-yl)amino]propionic acid
(2S)-2-[(17-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-methoxymorphinan-6β-yl)amino]propionic acid
(2S)-2-[(17-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-methoxymorphinan-6α-yl)amino]pentanedioic acid di-tert-butyl ester
(2S)-2-[(17-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-methoxymorphinan-6β-yl)amino]pentanedioic acid di-tert-butyl ester
(2S)-2-[(17-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-methoxymorphinan-6α-yl)amino]pentanedioic acid
(2S)-2-[(17-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-methoxymorphinan-6 (3-yl)amino]pentanedioic acid
(2S)-2-[(17-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-methoxymorphinan-6α-yl)amino]-4-methylpentanoic acid tert-butyl ester
(2S)-2-[(17-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-methoxymorphinan-6β-yl)amino]-4-methylpentanoic acid tert-butyl ester
(2S)-2-[(17-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-methoxymorphinan-6α-yl)amino]-4-methylpentanoic acid
(2S)-2-[(17-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-methoxymorphinan-6β-yl)amino]-4-methylpentanoic acid
(2S,3S)-2-[(17-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-methoxymorphinan-6α-yl)amino]-3-methylpentanoic acid tert-butyl ester
(2S,3S)-2-[(17-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-methoxymorphinan-6β-yl)amino]-3-methylpentanoic acid tert-butyl ester
(2S,3S)-2-[(17-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-methoxymorphinan-6α-yl)amino]-3-methylpentanoic acid
(2S,3S)-2-[(17-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-methoxymorphinan-6β-yl)amino]-3-methylpentanoic acid

### Claim 4 (depends on 1)

Compound according to claim 1, wherein one of R5 and R6 is hydrogen and the other one is selected among an acid group or a derivative thereof bearing residue and moieties forming, together with the nitrogen atom to which they are bound, a residue corresponding to an amino acid, an amino acid derivative and/or a dimer or oligomer thereof and/or a peptide comprising up to 30 amino acid units.

### Claim 5

Compounds of formula (Ia),
in which the substituents have the following meaning:
R1 is hydrogen; C1-C30, preferably C1-C12, more preferably C1-C6-alkyl; C2-C30, preferably C2-C12, more preferably C2-C6-alkenyl; C2-C30, preferably C2-C12, more preferably C2-C6-alkynyl; C1-C30, preferably C1-C12, more preferably C1-C6-monohydroxyalkyl; C2-C30, preferably C2-C12, more preferably C2-C6-dihydroxyalkyl; C3-C30, preferably C3-C12, more preferably C3-C6-trihydroxyalkyl; C4-C30, preferably C4-C16-cycloalkylalkyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkyl preferably is C1-C6-alkyl; C5-C30, preferably C5-C16-cycloalkylalkenyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkenyl preferably is C2-C6-alkenyl; C5-C30, preferably C5-C16-cycloalkylalkynyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkynyl preferably is C2-C6-alkynyl; C7-C30, preferably C7-C16-arylalkyl, where aryl preferably is C6-C10-aryl and alkyl preferably is C1-C6-alkyl; C8-C30, preferably C8-C16-arylalkenyl, where aryl preferably is C6-C10-aryl and alkenyl preferably is C2-C6-alkenyl; C8-C30, preferably C8-C16-arylalkynyl, where aryl preferably is C6-C10-aryl and alkynyl preferably is C2-C6-alkynyl;
the nitrogen joined with R1 can also be quarternised by two substituents R1, which can be the same or different and which are defined as previously shown, and whereby the second, quarternised substituent can additionally have the meaning hydroxyl, oxyl (N oxide) as well as alkoxyl;
R2, subject to the following definition of X, is hydrogen; C1-C30, preferably C1-C12, more preferably C1-C6-alkyl; C1-C30, preferably C1-C12, more preferably C1-C6-monohydroxyalkyl; C2-C30, preferably C2-C12, more preferably C2-C6-dihydroxyalkyl; C3-C30, preferably C3-C12, more preferably C3-C6-trihydroxyalkyl; C2-C30, preferably C2-C12, more preferably C2-C6-alkenyl; C2-C30, preferably C2-C12, more preferably C2-C6-alkynyl; C4-C30, preferably C4-C16-cycloalkylalkyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkyl preferably is C1-C6-alkyl; C5-C30, preferably C5-C16-cycloalkylalkenyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkenyl preferably is C2-C6-alkenyl; C5-C30, preferably C5-C16-cycloalkylalkynyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkynyl preferably is C2-C6-alkynyl; C7-C30, preferably C7-C16-arylalkyl, where aryl preferably is C6-C10-aryl and alkyl preferably is C1-C6-alkyl; C8-C30, preferably C8-C16-arylalkenyl, where aryl preferably is C6-C10-aryl and alkenyl preferably is C2-C6-alkenyl; C8-C30, preferably C8-C16-arylalkynyl, where aryl preferably is C6-C10-aryl and alkynyl preferably is C2-C6-alkynyl; C2-C30, preferably C2-C12, more preferably C2-C6-alkanoyl; C3-C30, preferably C3-C12, more preferably C3-C6-alkenoyl; C3-C30, preferably C3-C12, more preferably C3-C6-alkinoyl; C7-C30, preferably C7-C16-arylalkanoyl, where aryl preferably is C6-C10-aryl and alkanoyl preferably is C1-C6-alkanoyl; C9-C30, preferably C9-C16-arylalkenoyl, where aryl preferably is C6-C10-aryl and alkenoyl preferably is C3-C6-alkenoyl; C9-C30, preferably C9-C16-arylalkinoyl, where aryl preferably is C6-C10-aryl and alkinoyl preferably is C3-C6-alkinoyl;
R3 is hydrogen; C1-C30, preferably C1-C12, more preferably C1-C6-alkyl; C2-C30, preferably C2-C12, more preferably C2-C6-alkenyl; C7-C30, preferably C7-C16-arylalkyl, where aryl preferably is C6-C10-aryl and alkyl preferably is C1-C6-alkyl; C8-C30, preferably C8-C16-arylalkenyl, where aryl preferably is C6-C10-aryl and alkenyl preferably is C2-C6-alkenyl; alkoxyalkyl, where alkoxy is C1-C6-alkoxy and alkyl is C1-C6-alkyl; CO2(C1-C6-alkyl); CO2H; CH2OH;
R4, subject to the definition of Y, is hydrogen; C1-C30, preferably C1-C12, more preferably C1-C6-alkyl; C2-C30, preferably C2-C12, more preferably C2-C6-alkenyl; C2-C30, preferably C2-C12, more preferably C2-C6-alkynyl; C4-C30, preferably C4-C16-cycloalkylalkyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkyl preferably is C1-C6-alkyl; C5-C30, preferably C5-C16-cycloalkylalkenyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkenyl preferably is C2-C6-alkenyl; C5-C30, preferably C5-C16-cycloalkylalkynyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkynyl preferably is C2-C6-alkynyl; C7-C30, preferably C7-C16-arylalkyl, where aryl preferably is C6-C10-aryl and alkyl preferably is C1-C6-alkyl; C8-C30, preferably C8-C16-arylalkenyl, where aryl preferably is C6-C10-aryl and alkenyl preferably is C2-C6-alkenyl; C8-C30, preferably C8-C16-arylalkynyl, where aryl preferably is C6-C10-aryl and alkynyl preferably is C2-C6-alkynyl; C2-C30, preferably C2-C12, more preferably C2-C6-alkanoyl; C3-C30, preferably C3-C12, more preferably C3-C6-alkenoyl; C3-C30, preferably C3-C12, more preferably C3-C6-alkinoyl; C7-C30, preferably C7-C16-arylalkanoyl, where aryl preferably is C6-C10-aryl and alkanoyl preferably is C1-C6-alkanoyl; C9-C30, preferably C9-C16-arylalkenoyl, where aryl preferably is C6-C10-aryl and alkenoyl preferably is C3-C6-alkenoyl; C9-C30, preferably C9-C16-arylalkinoyl, where aryl preferably is C6-C10-aryl and alkinoyl preferably is C3-C6-alkinoyl; iminomethyl, formamidinyl, C1-C30, preferably C1-C12, more preferably C1-C6—N-alkyl- and N,N′-dialkylformamidinyl; C2-C30, preferably C2-C12, more preferably C2-C6—N-alkenyl- and N,N′-dialkenylformamidinyl; C2-C30, preferably C2-C12, more preferably C2-C6—N-alkynyl- and N,N′-dialkynylformamidinyl; C4-C30, preferably C4-C16—N-cycloalkylalkyl- and N,N′-dicycloalkylalkylformamidinyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkyl preferably is C1-C6-alkyl; C5-C30, preferably C5-C16—N-cylcoalkylalkenyl- and N,N′-dicycloalkylalkenylformamidinyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkenyl preferably is C2-C6-alkenyl; C5-C30, preferably C5-C16—N-cycloalkylalkynyl- and N,N′-dicycloalkylalkynylformamidinyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkynyl preferably is C2-C6-alkynyl; C7-C30, preferably C7-C16—N-arylalkyl- and N,N′-diarylalkylformamidinyl, where aryl preferably is C6-C10-aryl and alkyl preferably is C1-C6-alkyl;
R5 and R6, which can be the same or different, are selected from hydrogen; C1-C30, preferably C1-C12, more preferably C1-C6-alkyl; C2-C30, preferably C2-C12, more preferably C2-C6-alkenyl; C2-C30, preferably C2-C12, more preferably C2-C6-alkynyl; C4-C30, preferably C4-C16-cycloalkylalkyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkyl preferably is C1-C6-alkyl; C5-C30, preferably C5-C16-cycloalkylalkenyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkenyl preferably is C2-C6-alkenyl; C5-C30, preferably C5-C16-cycloalkylalkynyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkynyl preferably is C2-C6-alkynyl; C7-C30, preferably C7-C16-arylalkyl, where aryl preferably is C6-C10-aryl and alkyl preferably is C1-C6-alkyl; C8-C30, preferably C8-C16-arylalkenyl, where aryl preferably is C6-C10-aryl and alkenyl preferably is C2-C6-alkenyl; C8-C30, preferably C8-C16-arylalkynyl, where aryl preferably is C6-C10-aryl and alkynyl preferably is C2-C6-alkynyl; furthermore, CH(A′)CO2B, where A′ is hydrogen; hydroxyl; C1-C30, preferably C1-C12, more preferably C1-C6-alkyl; C2-C30, preferably C2-C12, more preferably C2-C6-alkenyl; C2-C30, preferably C2-C12, more preferably C2-C6-alkynyl; C4-C30, preferably C4-C16-cycloalkylalkyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkyl preferably is C1-C6-alkyl; C5-C30, preferably C5-C16-cycloalkylalkenyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkenyl preferably is C2-C6-alkenyl; C5-C30, preferably C5-C16-cycloalkylalkynyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkynyl preferably is C2-C6-alkynyl; C7-C30, preferably C7-C16-arylalkyl, where aryl preferably is C6-C10-aryl and alkyl preferably is C1-C6-alkyl; C8-C30, preferably C8-C16-arylalkenyl, where aryl preferably is C6-C10-aryl and alkenyl preferably is C2-C6-alkenyl; C8-C30, preferably C8-C16-arylalkynyl, where aryl preferably is C6-C10-aryl and alkynyl preferably is C2-C6-alkynyl; amino; C1-C30, preferably C1-C12, more preferably C1-C6-alkylamino; guanidino; C1-C30, preferably C1-C12, more preferably C1-C6-alkyl-CO2B; and where B is hydrogen; C1-C30-, preferably C1-C12, more preferably C1-C6-alkyl; C2-C30-, preferably C2-C12, more preferably C2-C6-alkenyl; C2-C30-, preferably C2-C12, more preferably C2-C6-alkynyl; C4-C30, preferably C4-C16-cycloalkylalkyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkyl preferably is C1-C6-alkyl; C5-C30, preferably C5-C16-cycloalkylalkenyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkenyl preferably is C2-C6-alkenyl; C5-C30, preferably C5-C16-cycloalkylalkynyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkynyl preferably is C2-C6-alkynyl; C7-C30, preferably C7-C16-arylalkyl, where aryl preferably is C6-C10-aryl and alkyl preferably is C1-C6-alkyl; C8-C30, preferably C8-C16-arylalkenyl, where aryl preferably is C6-C10-aryl and alkenyl preferably is C2-C6-alkenyl; C8-C30, preferably C8-C16-arylalkynyl, where aryl preferably is C6-C10-aryl and alkynyl preferably is C2-C6-alkynyl; phenyl; substituted phenyl; CH2OCO—C1-C6-alkyl; CH(C1-C6-alkyl)OCO—C1-C6-alkyl; CH2OCOO—C1-C6-alkyl; CH(C1-C6-alkyl)OCOO—C1-C6-alkyl; CH2CON(C1-C6-alkyl)2; CH(C1-C6-alkyl)CON(C1-C6-alkyl)2; phthalidyl, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl, furthermore CH(A)SO3B, whereby A and B are defined as above; also iminomethyl, formamidinyl, C1-C30, preferably C1-C12, more preferably C1-C6—N-alkyl- and N,N′-dialkylformamidinyl; C2-C30, preferably C2-C12, more preferably C2-C6—N-alkenyl- and N,N′-dialkenylformamidinyl; C2-C30, preferably C2-C12, more preferably C2-C6—N-alkynyl- and N,N′-dialkynylformamidinyl; C4-C30, preferably C4-C16—N-cycloalkylalkyl- and N,N′-dicycloalkylalkylformamidinyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkyl preferably is C1-C6-alkyl; C5-C30, preferably C5-C16—N-cylcoalkylalkenyl- and N,N′-dicycloalkylalkenylformamidinyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkenyl preferably is C2-C6-alkenyl; C5-C30, preferably C5-C16—N-cycloalkylalkynyl- and N,N′-dicycloalkylalkynylformamidinyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkynyl preferably is C2-C6-alkynyl; C7-C30, preferably C7-C16—N-arylalkyl- and N,N′-diarylalkylformamidinyl, where aryl preferably is C6-C10-aryl and alkyl preferably is C1-C6-alkyl; C8-C30, preferably C8-C16—N-arylalkenyl- and N,N′-diarylalkenylformamidinyl, where aryl preferably is C6-C10-aryl and alkenyl preferably is C2-C6-alkenyl; C8-C30, preferably C8-C16—N-arylalkynyl- and N,N′-diarylalkynylformamidinyl, where aryl preferably is C6-C10-aryl and alkynyl preferably is C2-C6-alkynyl; C2-C30, preferably C2-C12, more preferably C2-C7—N-alkyloxycarbonyl- and N,N′-bis(alkyloxycarbonyl)formamidinyl; C3-C30, preferably C3-C12, more preferably C3-C8—N-alkenyloxycarbonyl- and N,N′-bis(alkenyloxycarbonyl)formamidinyl; C3-C30, preferably C3-C12, more preferably C3-C8—N-alkynyloxycarbonyl- and N,N′-bis(alkynyloxycarbonyl)formamidinyl; C8-C30, preferably C8-C17—N-arylalkyloxycarbonyl- and N,N′-bis(arylalkyloxycarbonyl)formamidinyl, where aryl preferably is C6-C10-aryl and alkyloxy preferably is C1-C6-alkyloxy; C9-C30, preferably C9-C17—N-arylalkenyloxycarbonyl- and N,N′-bis(arylalkenyloxycarbonyl)formamidinyl, where aryl preferably is C6-C10-aryl and alkenyloxy preferably is C2-C6-alkenyloxy; C9-C30, preferably C9-C17—N-arylalkynyloxycarbonyl- and N,N′-bis(arylalkynyloxycarbonyl)formamidinyl, where aryl preferably is C6-C10-aryl and alkynyloxy preferably is C2-C6-alkynyloxy; C1-C30, preferably C1-C12, more preferably C1-C6—N-alkanoyl- and N,N′-dialkanoylformamidinyl; C3-C30, preferably C3-C12, more preferably C3-C6—N-alkenoyl- and N,N′-dialkenoylformamidinyl; C3-C30, preferably C3-C12, more preferably C3-C6—N-alkinoyl- and N,N′-dialkinoylformamidinyl; C7-C30, preferably C7-C16—N-arylalkanoyl- and N,N′-diarylalkanoylformamidinyl, where aryl preferably is C6-C10-aryl and alkanoyl preferably is C1-C6-alkyl; C9-C30, preferably C9-C16—N-arylalkenoyl- and N,N′-diarylalkenoylformamidinyl, where aryl preferably is C6-C10-aryl and alkenoyl preferably is C3-C6-alkenoyl; C9-C30, preferably C9-C16—N-arylalkinoyl- and N,N′-diarylalkinoylformamidinyl, where aryl preferably is C6-C10-aryl and alkinoyl preferably is C3-C6-alkinoyl; 4,5-dihydro-1H-imidazol-2-yl, 1,4,5,6-tetrahydropyrimidin-2-yl, 4,5,6,7-tetrahydro-1H-[1,3]diazepin-2-yl;
X is oxygen, sulphur or methylene or the group (X—R2) is H and
Y is oxygen or the group (Y—R4) is H;
and pharmaceutically acceptable acid addition salts as well as base addition salts and easily accessible derivatives (e.g. esters or amides of amino acid derivatives), as well as polymorphic forms thereof.

### Claim 6 (depends on 5)

Compounds of claim 5 in which R1 is C1-C6-alkyl; R2 is C1-C6-alkyl or C7-C16-arylalkyl, where aryl is C6-C10-aryl and alkyl is C1-C6-alkyl; R3, R4 and R6 are hydrogen; R5 is CH(A)CO2B where A is hydrogen; hydroxyl; C1-C6-alkyl; C7-C16-arylalkyl, where aryl is C6-C10-aryl and alkyl is C1-C6-alkyl; amino; or guanidino; B is hydrogen or C1-C6-alkyl; R5 can furthermore be formamidinyl; C2-C7-(alkyloxycarbonyl)formamidinyl; C3-C8-(alkenyloxycarbonyl)formamidinyl; C3-C8-(alkynyloxycarbonyl)formamidinyl; C8-C17-(arylalkyloxycarbonyl)formamidinyl, where aryl is C6-C10-aryl and alkyloxy is C1-C6-alkyloxy; C9-C17-(arylalkenyloxycarbonyl)formamidinyl, where aryl is C6-C10-aryl and alkenyloxy is C2-C6-alkenyloxy; C9-C17-(arylalkynyloxycarbonyl)formamidinyl, where aryl is C6-C10-aryl and alkynyloxy is C2-C6-alkynyloxy.

### Claim 7 (depends on 1)

Compounds according to claim 1, wherein X is oxygen.

### Claim 8 (depends on 1)

Compounds according to claim 1, wherein the compound is present as base addition salt.

### Claim 9 (depends on 8)

Compounds according to claim 8, wherein the base addition salt is selected among lithium salts, sodium salts, potassium salts, beryllium salts, magnesium salts, calcium salts, strontium salts, aluminum salts and zinc salts, C1-C30 monoalkylammonium salts, C1-C30 dialkylammonium salts, C1-C30 trialkylammonium salts, C1-C30 tetraalkylammonium salts; C2-C30 monoalkenylammonium salts, C2-C30 dialkenylammonium salts, C2-C30 trialkenylammonium salts, C2-C30 tetraalkenylammonium salts; C2-C30 monoalkynylammonium salts, C2-C30 dialkynylammonium salts, C2-C30 trialkynylammonium salts, C2-C30 tetraalkynylammonium salts; C4-C30 mono(cycloalkylalkylammonium) salts, C4-C30 di(cycloalkylalkylammonium) salts, C4-C30 tri(cycloalkylalkylammonium) salts, C4-C30 tetra(cycloalkylalkylammonium) salts, where cycloalkyl is C3-C10-cycloalkyl and alkyl is C1-C27-alkyl; C5-C30 mono(cycloalkylalkenylammonium) salts, C5-C30 di(cycloalkylalkenylammonium) salts, C5-C30 tri(cycloalkylalkenylammonium) salts, C5-C30 tetra(cycloalkylalkenylammonium) salts, where cycloalkyl is C3-C10-cycloalkyl and alkenyl is C2-C27-alkenyl; C5-C30 mono(cycloalkylalkynylammonium) salts, C5-C30 di(cycloalkylalkynylammonium) salts, C5-C30 tri(cycloalkylalkynylammonium) salts, C5-C30 tetra(cycloalkylalkynylammonium) salts, where cycloalkyl is C3-C10-cycloalkyl and alkynyl is C2-C27-alkynyl; C7-C30 mono(arylalkylammonium) salts, C7-C30 di(arylalkylammonium) salts, C7-C30 tri(arylalkylammonium) salts, C7-C30 tetra(arylalkylammonium) salts, where aryl is C6-C10-aryl and alkyl is C1-C24-alkyl; C8-C30 mono(arylalkenylammonium) salts, C8-C30 di(arylalkenylammonium) salts, C8-C30 tri(arylalkenylammonium) salts, C8-C30 tetra(arylalkenylammonium) salts, where aryl is C6-C10-aryl and alkenyl is C2-C24-alkenyl; C8-C30 mono(arylalkynylammonium) salts, C8-C30 di(arylalkynylammonium) salts, C8-C30 tri(arylalkynylammonium) salts, C8-C30 tetra(arylalkynylammonium) salts, where aryl is C6-C10-aryl and alkynyl is C2-C24-alkynyl, combinations of the ammonium salts listed above, and salts derived from heterocyclic nitrogen bases.

### Claim 10 (depends on 5)

Compounds of claim 5, selected from: (4,5α-epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6α-ylamino)-acetic acid-tert.-butylester, (4,5α-epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6β-ylamino)-acetic acid-tert.-butylester, (4,5α-epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6α-ylamino)-acetic acid, (4,5α-epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6β-ylamino)-acetic acid, (2S)-2-(4,5α-epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6α-ylamino)-propionic acid-tert.-butylester, (2S)-2-(4,5α-epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6β-ylamino)-propionic acid-tert.-butylester, (2S)-2-(4,5α-epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6α-ylamino)-propionic acid, (2S)-2-(4,5α-epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6β-ylamino)-propionic acid, (2S)-2-(4,5α-epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6α-ylamino)-3′-phenylpropionic acid-tert.-butylester, (2S)-2-(4,5α-epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6 (3-ylamino)-3′-phenylpropionic acid-tert.-butylester, (2S)-2-(4,5α-epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6α-ylamino)-3′-phenylpropionic acid, (2S)-2-(4,5α-epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6β-ylamino)-3′-phenylpropionic acid, 6α-amino-4,5α-epoxy-14β-methoxy-17-methylmorphinan-3-ol, 6β-dibenzylamino-4,5α-epoxy-14β-methoxy-17-methylmorphinan-3-ol, 6β-amino-4,5α-epoxy-14β-methoxy-17-methylmorphinan-3-ol, 4,5α-epoxy-6β-[N,N′-bis-(tert.-butoxycarbonyl)guanidinyl]-14β-methoxy-17-methylmorphinan-3-ol, 4,5α-epoxy-6β-guanidinyl-14β-methoxy-17-methylmorphinan-3-ol, 4,5α-epoxy-6β-[N,N′-bis-(tert.-butoxycarbonyl)guanidinyl]-14β-methoxy-17-methylmorphinan-3-ol, 4,5α-epoxy-6α-guanidinyl-14β-methoxy-17-methylmorphinan-3-ol, 1,3-bis-(tert.-butoxycarbonyl)-2-{4,5α-epoxy-6β-[N,N′-bis-(tert.-butoxycarbonyl)guanidinyl]-14β-methoxy-17-methylmorphinan-3-yl}-isourea, 1,3-bis-(tert.-butoxycarbonyl)-2-{4,5α-epoxy-6α-[N,N′-bis-(tert.-butoxycarbonyl)guanidinyl]-14β-methoxy-17-methylmorphinan-3-yl}-isourea, (4,5α-epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6α-ylamino)-acetic acid-ethylester dihydrochloride, (4,5α-epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6β-ylamino)-acetic acid-ethylester dihydrochloride, (4,5α-epoxy-3-hydroxy-14β-ethoxy-17-methylmorphinan-6α-ylamino)-acetic acid-tert.-butylester, (4,5α-epoxy-3-hydroxy-14β-ethoxy-17-methylmorphinan-6β-ylamino)-acetic acid-tert.-butylester, (4,5α-epoxy-3-hydroxy-14β-ethoxy-17-methylmorphinan-6α-ylamino)-acetic acid bis(tetrafluoroborate), (4,5α-epoxy-3-hydroxy-14β-ethoxy-17-methylmorphinan-6β-ylamino)-acetic acid bis(tetrafluoroborate), (2S)-2-(17-cyclopropylmethyl-4,5α-epoxy-3,14β-dihydroxymorphinan-6β-ylamino)-3-phenylpropionic acid-tert.-butylester, (2S)-2-(17-cyclopropylmethyl-4,5α-epoxy-3,14β-dihydroxymorphinan-6β-ylamino)-3-phenylpropionic acid bis(tetrafluoroborate), {17-cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-[(3-phenylpropyl)oxy]-morphinan-6α-ylamino}-acetic acid-tert.-butylester, {17-cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-[(3-phenylpropyl)oxy]-morphinan-6α-ylamino}-acetic acid-tert.-butylester, (2S)-2-(17-cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-[(3-phenylpropyl)oxy]-morphinan-6α-ylamino)-3-phenylpropionic acid-tert.-butylester, {17-cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-[(3-phenylpropyl)oxy]-morphinan-6β-ylamino}-acetic acid dihydrochloride; or any pharmaceutically acceptable salt or an easily accessible derivative of them.

### Claim 11 (depends on 5)

Compounds of claim 5 selected from
2-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6α-yl)amino]acetic acid dihydrochloride
2-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6β-yl)amino]acetic acid dihydrochloride
2-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6β-yl)amino]acetic acid dihydrochloride monohydrate ethanolate
(2S)-2-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6α-yl)amino]propionoic acid dihydrochloride
(2S)-2-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6β-yl)amino]propionoic acid dihydrochloride
(2S)-2-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6α-yl)amino]-3-phenylpropionoic acid dihydrochloride
(2S)-2-[(4,5α-Epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6β-yl)amino]-3-phenylpropionoic acid dihydrochloride

### Claim 12 (depends on 1)

Composition, comprising a compound of claim 1 and/or a pharmaceutically acceptable acid addition salt or base addition salt of it, together with a pharmaceutically acceptable carrier substance.

### Claim 13 (depends on 1)

Compounds according to claim 1 as medicament.

### Claim 14 (depends on 1)

Use of a compound of claim 1 for the manufacture of a medicament for the treatment of pain.

### Claim 15 (depends on 1)

Use of a compound of claim 1 for the manufacture of a medicament for the treatment of intestinal diseases, in particular chronic inflammation of the small and large intestines (irritable colon syndrome—colon irritabile, colitis ulcerosa, morbus Crohn), diarrhoea or obstipation.

### Claim 16 (depends on 1)

Use of a compound of claim 1 for the manufacture of a medicament for the treatment of rheumatic diseases, including rheumatoid arthritis, osteoarthritis, arthrosis, spondylosis, lumbago, lupus erythematosus, spondylarthropathy.

### Claim 17 (depends on 1)

Use of a compound of claim 1 for the manufacture of a medicament for the treatment of tumours and cancer as well as for the treatment of obesity and overweight, and also for the suppression of rejection of transplants after transplantations and for the prevention and treatment of intestinal obstruction (ileus).

### Claim 18 (depends on 1)

Use of a compound of claim 1 for the manufacture of a medicament for the withdrawal from drug addiction, for example, to opiates, cocaine or alcohol and for the treatment of psychic diseases.

### Claim 19

Compounds of formula (VIII),
in which the substituents have the following meaning:
R1 is hydrogen; C1-C30, preferably C1-C12, more preferably C1-C6-alkyl; C2-C30, preferably C2-C12, more preferably C2-C6-alkenyl; C2-C30, preferably C2-C12, more preferably C2-C6-alkynyl; C1-C30, preferably C1-C12, more preferably C1-C6-monohydroxyalkyl; C2-C30, preferably C2-C12, more preferably C2-C6-dihydroxyalkyl; C3-C30, preferably C3-C12, more preferably C3-C6-trihydroxyalkyl; C4-C30, preferably C4-C16-cycloalkylalkyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkyl preferably is C1-C6-alkyl; C5-C30, preferably C5-C16-cycloalkylalkenyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkenyl preferably is C2-C6-alkenyl; C5-C30, preferably C5-C16-cycloalkylalkynyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkynyl preferably is C2-C6-alkynyl; C7-C30, preferably C7-C16-arylalkyl, where aryl preferably is C6-C10-aryl and alkyl preferably is C1-C6-alkyl; C8-C30, preferably C8-C16-arylalkenyl, where aryl preferably is C6-C10-aryl and alkenyl preferably is C2-C6-alkenyl; C8-C30, preferably C8-C16-arylalkynyl, where aryl preferably is C6-C10-aryl and alkynyl preferably is C2-C6-alkynyl;
the nitrogen joined with R1 can also be quarternised by two substituents R1, which can be the same or different and which are defined as previously shown, and whereby the second, quarternised substituent can additionally have the meaning hydroxyl, oxyl (N-oxide) as well as alkoxyl;
R2, subject to the following definition of X, is hydrogen; C1-C30, preferably C1-C12, more preferably C1-C6-alkyl; C1-C30, preferably C1-C12, more preferably C1-C6-monohydroxyalkyl; C2-C30, preferably C2-C12, more preferably C2-C6-dihydroxyalkyl; C3-C30, preferably C3-C12, more preferably C3-C6-trihydroxyalkyl; C2-C30, preferably C2-C12, more preferably C2-C6-alkenyl; C2-C30, preferably C2-C12, more preferably C2-C6-alkynyl; C4-C30, preferably C4-C16-cycloalkylalkyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkyl preferably is C1-C6-alkyl; C5-C30, preferably C5-C16-cycloalkylalkenyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkenyl preferably is C2-C6-alkenyl; C5-C30, preferably C5-C16-cycloalkylalkynyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkynyl preferably is C2-C6-alkynyl; C7-C30, preferably C7-C16-arylalkyl, where aryl preferably is C6-C10-aryl and alkyl preferably is C1-C6-alkyl; C8-C30, preferably C8-C16-arylalkenyl, where aryl preferably is C6-C10-aryl and alkenyl preferably is C2-C6-alkenyl; C8-C30, preferably C8-C16-arylalkynyl, where aryl preferably is C6-C10-aryl and alkynyl preferably is C2-C6-alkynyl; C2-C30, preferably C2-C12, more preferably C2-C6-alkanoyl; C3-C30, preferably C3-C12, more preferably C3-C6-alkenoyl; C3-C30, preferably C3-C12, more preferably C3-C6-alkinoyl; C7-C30, preferably C7-C16-arylalkanoyl, where aryl preferably is C6-C10-aryl and alkanoyl preferably is C1-C6-alkanoyl; C9-C30, preferably C9-C16-arylalkenoyl, where aryl preferably is C6-C10-aryl and alkenoyl preferably is C3-C6-alkenoyl; C9-C30, preferably C9-C16-arylalkinoyl, where aryl preferably is C6-C10-aryl and alkinoyl preferably is C3-C6-alkinoyl;
R3 is hydrogen; C1-C30, preferably C1-C12, more preferably C1-C6-alkyl; C2-C30, preferably C2-C12, more preferably C2-C6-alkenyl; C7-C30, preferably C7-C16-arylalkyl, where aryl preferably is C6-C10-aryl and alkyl preferably is C1-C6-alkyl; C8-C30, preferably C8-C16-arylalkenyl, where aryl preferably is C6-C10-aryl and alkenyl preferably is C2-C6-alkenyl; alkoxyalkyl, where alkoxy is C1-C6-alkoxy and alkyl is C1-C6-alkyl; CO2(C1-C6-alkyl); CO2H; CH2OH;
R4, subject to the definition of Y, is hydrogen; C1-C30, preferably C1-C12, more preferably C1-C6-alkyl; C2-C30, preferably C2-C12, more preferably C2-C6-alkenyl; C2-C30, preferably C2-C12, more preferably C2-C6-alkynyl; C4-C30, preferably C4-C16-cycloalkylalkyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkyl preferably is C1-C6-alkyl; C5-C30, preferably C5-C16-cycloalkylalkenyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkenyl preferably is C2-C6-alkenyl; C5-C30, preferably C5-C16-cycloalkylalkynyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkynyl preferably is C2-C6-alkynyl; C7-C30, preferably C7-C16-arylalkyl, where aryl preferably is C6-C10-aryl and alkyl preferably is C1-C6-alkyl; C8-C30, preferably C8-C16-arylalkenyl, where aryl preferably is C6-C10-aryl and alkenyl preferably is C2-C6-alkenyl; C8-C30, preferably C8-C16-arylalkynyl, where aryl preferably is C6-C10-aryl and alkynyl preferably is C2-C6-alkynyl; C2-C30, preferably C2-C12, more preferably C2-C6-alkanoyl; C3-C30, preferably C3-C12, more preferably C3-C6-alkenoyl; C3-C30, preferably C3-C12, more preferably C3-C6-alkinoyl; C7-C30, preferably C7-C16-arylalkanoyl, where aryl preferably is C6-C10-aryl and alkanoyl preferably is C1-C6-alkanoyl; C9-C30, preferably C9-C16-arylalkenoyl, where aryl preferably is C6-C10-aryl and alkenoyl preferably is C3-C6-alkenoyl; C9-C30, preferably C9-C16-arylalkinoyl, where aryl preferably is C6-C10-aryl and alkinoyl preferably is C3-C6-alkinoyl; iminomethyl, formamidinyl, C1-C30, preferably C1-C12, more preferably C1-C6—N-alkyl- and N,N′-dialkylformamidinyl; C2-C30, preferably C2-C12, more preferably C2-C6—N-alkenyl- and N,N′-dialkenylformamidinyl; C2-C30, preferably C2-C12, more preferably C2-C6—N-alkynyl- and N,N′-dialkynylformamidinyl; C4-C30, preferably C4-C16—N-cycloalkylalkyl- and N,N′-dicycloalkylalkylformamidinyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkyl preferably is C1-C6-alkyl; C5-C30, preferably C5-C16—N-cylcoalkylalkenyl- and N,N′-dicycloalkylalkenylformamidinyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkenyl preferably is C2-C6-alkenyl; C5-C30, preferably C5-C16—N-cycloalkylalkynyl- and N,N′-dicycloalkylalkynylformamidinyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkynyl preferably is C2-C6-alkynyl; C7-C30, preferably C7-C16—N-arylalkyl- and N,N′-diarylalkylformamidinyl, where aryl preferably is C6-C10-aryl and alkyl preferably is C1-C6-alkyl;
R5 and R6, which can be the same or different, are selected from hydrogen; C1-C30, preferably C1-C12, more preferably C1-C6-alkyl; C2-C30, preferably C2-C12, more preferably C2-C6-alkenyl; C2-C30, preferably C2-C12, more preferably C2-C6-alkynyl; C4-C30, preferably C4-C16-cycloalkylalkyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkyl preferably is C1-C6-alkyl; C5-C30, preferably C5-C16-cycloalkylalkenyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkenyl preferably is C2-C6-alkenyl; C5-C30, preferably C5-C16-cycloalkylalkynyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkynyl preferably is C2-C6-alkynyl; C7-C30, preferably C7-C16-arylalkyl, where aryl preferably is C6-C10-aryl and alkyl preferably is C1-C6-alkyl; C8-C30, preferably C8-C16-arylalkenyl, where aryl preferably is C6-C10-aryl and alkenyl preferably is C2-C6-alkenyl; C8-C30, preferably C8-C16-arylalkynyl, where aryl preferably is C6-C10-aryl and alkynyl preferably is C2-C6-alkynyl; furthermore, CH(A′)CO2B, where A′ is hydrogen; hydroxyl; C1-C30, preferably C1-C12, more preferably C1-C6-alkyl; C2-C30, preferably C2-C12, more preferably C2-C6-alkenyl; C2-C30, preferably C2-C12, more preferably C2-C6-alkynyl; C4-C30, preferably C4-C16-cycloalkylalkyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkyl preferably is C1-C6-alkyl; C5-C30, preferably C5-C16-cycloalkylalkenyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkenyl preferably is C2-C6-alkenyl; C5-C30, preferably C5-C16-cycloalkylalkynyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkynyl preferably is C2-C6-alkynyl; C7-C30, preferably C7-C16-arylalkyl, where aryl preferably is C6-C10-aryl and alkyl preferably is C1-C6-alkyl; C8-C30, preferably C8-C16-arylalkenyl, where aryl preferably is C6-C10-aryl and alkenyl preferably is C2-C6-alkenyl; C8-C30, preferably C8-C16-arylalkynyl, where aryl preferably is C6-C10-aryl and alkynyl preferably is C2-C6-alkynyl; amino; C1-C30, preferably C1-C12, more preferably C1-C6-alkylamino; guanidino; C1-C30, preferably C1-C12, more preferably C1-C6-alkyl-CO2B; and where B is hydrogen; C1-C30-, preferably C1-C12, more preferably C1-C6-alkyl; C2-C30-, preferably C2-C12, more preferably C2-C6-alkenyl; C2-C30-, preferably C2-C12, more preferably C2-C6-alkynyl; C4-C30, preferably C4-C16-cycloalkylalkyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkyl preferably is C1-C6-alkyl; C5-C30, preferably C5-C16-cycloalkylalkenyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkenyl preferably is C2-C6-alkenyl; C5-C30, preferably C5-C16-cycloalkylalkynyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkynyl preferably is C2-C6-alkynyl; C7-C30, preferably C7-C16-arylalkyl, where aryl preferably is C6-C10-aryl and alkyl preferably is C1-C6-alkyl; C8-C30, preferably C8-C16-arylalkenyl, where aryl preferably is C6-C10-aryl and alkenyl preferably is C2-C6-alkenyl; C8-C30, preferably C8-C16-arylalkynyl, where aryl preferably is C6-C10-aryl and alkynyl preferably is C2-C6-alkynyl; phenyl; substituted phenyl; CH2OCO—C1-C6-alkyl; CH(C1-C6-alkyl)OCO—C1-C6-alkyl; CH2OCOO—C1-C6-alkyl; CH(C1-C6-alkyl)OCOO—C1-C6-alkyl; CH2CON(C1-C6-alkyl)2; CH(C1-C6-alkyl)CON(C1-C6-alkyl)2; phthalidyl, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl, furthermore CH(A)SO3B, whereby A and B are defined as above; also iminomethyl, formamidinyl, C1-C30, preferably C1-C12, more preferably C1-C6—N-alkyl- and N,N′-dialkylformamidinyl; C2-C30, preferably C2-C12, more preferably C2-C6—N-alkenyl- and N,N′-dialkenylformamidinyl; C2-C30, preferably C2-C12, more preferably C2-C6—N-alkynyl- and N,N′-dialkynylformamidinyl; C4-C30, preferably C4-C16—N-cycloalkylalkyl- and N,N′-dicycloalkylalkylformamidinyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkyl preferably is C1-C6-alkyl; C5-C30, preferably C5-C16—N-cylcoalkylalkenyl- and N,N′-dicycloalkylalkenylformamidinyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkenyl preferably is C2-C6-alkenyl; C5-C30, preferably C5-C16—N-cycloalkylalkynyl- and N,N′-dicycloalkylalkynylformamidinyl, where cycloalkyl preferably is C3-C10-cycloalkyl and alkynyl preferably is C2-C6-alkynyl; C7-C30, preferably C7-C16—N-arylalkyl- and N,N′-diarylalkylformamidinyl, where aryl preferably is C6-C10-aryl and alkyl preferably is C1-C6-alkyl; C8-C30, preferably C8-C16—N-arylalkenyl- and N,N′-diarylalkenylformamidinyl, where aryl preferably is C6-C10-aryl and alkenyl preferably is C2-C6-alkenyl; C8-C30, preferably C8-C16—N-arylalkynyl- and N,N′-diarylalkynylformamidinyl, where aryl preferably is C6-C10-aryl and alkynyl preferably is C2-C6-alkynyl; C2-C30, preferably C2-C12, more preferably C2-C7—N-alkyloxycarbonyl- and N,N′-bis(alkyloxycarbonyl)formamidinyl; C3-C30, preferably C3-C12, more preferably C3-C8—N-alkenyloxycarbonyl- and N,N′-bis(alkenyloxycarbonyl)formamidinyl; C3-C30, preferably C3-C12, more preferably C3-C8—N-alkynyloxycarbonyl- and N,N′-bis(alkynyloxycarbonyl)formamidinyl; C8-C30, preferably C8-C17—N-arylalkyloxycarbonyl- and N,N′-bis(arylalkyloxycarbonyl)formamidinyl, where aryl preferably is C6-C10-aryl and alkyloxy preferably is C1-C6-alkyloxy; C9-C30, preferably C9-C17—N-arylalkenyloxycarbonyl- and N,N′-bis(arylalkenyloxycarbonyl)formamidinyl, where aryl preferably is C6-C10-aryl and alkenyloxy preferably is C2-C6-alkenyloxy; C9-C30, preferably C9-C17—N-arylalkynyloxycarbonyl- and N,N′-bis(arylalkynyloxycarbonyl)formamidinyl, where aryl preferably is C6-C10-aryl and alkynyloxy preferably is C2-C6-alkynyloxy; C1-C30, preferably C1-C12, more preferably C1-C6—N-alkanoyl- and N,N′-dialkanoylformamidinyl; C3-C30, preferably C3-C12, more preferably C3-C6—N-alkenoyl- and N,N′-dialkenoylformamidinyl; C3-C30, preferably C3-C12, more preferably C3-C6—N-alkinoyl- and N,N′-dialkinoylformamidinyl; C7-C30, preferably C7-C16—N-arylalkanoyl- and N,N′-diarylalkanoylformamidinyl, where aryl preferably is C6-C10-aryl and alkanoyl preferably is C1-C6-alkyl; C9-C30, preferably C9-C16—N-arylalkenoyl- and N,N′-diarylalkenoylformamidinyl, where aryl preferably is C6-C10-aryl and alkenoyl preferably is C3-C6-alkenoyl; C9-C30, preferably C9-C16—N-arylalkinoyl- and N,N′-diarylalkinoylformamidinyl, where aryl preferably is C6-C10-aryl and alkinoyl preferably is C3-C6-alkinoyl; 4,5-dihydro-1H-imidazol-2-yl, 1,4,5,6-tetrahydropyrimidin-2-yl, 4,5,6,7-tetrahydro-1H-[1,3]diazepin-2-yl; and residues selected from the following group (VIIIa): (C1-C30-alkyl)CO2B; (C1-C30-alkenyl)CO2B; (C1-C30-alkynyl)CO2B; (C4-C30-cycloalkylalkyl)CO2B, where cycloalkyl is C3-C10-cycloalkyl and alkyl is C1-C27-alkyl; (C4-C30-cycloalkylalkenyl)CO2B, where cycloalkyl is C3-C10-cycloalkyl and alkenyl is C2-C27-alkenyl; (C4-C30-cycloalkylalkynyl)CO2B, where cycloalkyl is C3-C10-cycloalkyl and alkynyl is C2-C27-alkynyl; (C7-C30-arylalkyl)CO2B, where aryl is C6-C10-aryl and alkyl is C1-C24-alkyl; (C8-C30-arylalkenyl)CO2B, where aryl is C6-C10-aryl and alkenyl is C2-C24-alkenyl; (C8-C30-arylalkynyl)CO2B, where aryl is C6-C10-aryl and alkynyl is C2-C24-alkynyl;
[(C1-C30-alkyl)CO2B]CO2B; [(C1-C30-alkenyl)CO2B]CO2B; [(C1-C30-alkynyl)CO2B]CO2B; [(C4-C30-cycloalkylalkyl)CO2B]CO2B, where cycloalkyl is C3-C10-cycloalkyl and alkyl is C1-C27-alkyl; [(C4-C30-cycloalkylalkenyl)CO2B]CO2B, where cycloalkyl is C3-C10-cycloalkyl and alkenyl is C2-C27-alkenyl; [(C4-C30-cycloalkylalkynyl)CO2B]CO2B, where cycloalkyl is C3-C10-cycloalkyl and alkynyl is C2-C27-alkynyl; [(C7-C30-arylalkyl)CO2B]CO2B, where aryl is C6-C10-aryl and alkyl is C1-C24-alkyl; [(C7-C30-arylalkenyl)CO2B]CO2B, where aryl is C6-C10-aryl and alkenyl is C2-C24-alkenyl; [(C7-C30-arylalkynyl)CO2B]CO2B, where aryl is C6-C10-aryl and alkynyl is C2-C24-alkynyl; [(C1-C30-alkyl)CONH2]CO2B; [(C1-C30-alkenyl)CONH2]CO2B; [(C1-C30-alkynyl)CONH2]CO2B; [(C4-C30-cycloalkylalkyl)CONH2]CO2B, where cycloalkyl is C3-C10-cycloalkyl and alkyl is C1-C27-alkyl; [(C4-C30-cycloalkylalkenyl)CONH2]CO2B, where cycloalkyl is C3-C10-cycloalkyl and alkenyl is C2-C27-alkenyl; [(C4-C30-cycloalkylalkynyl)CONH2]CO2B, where cycloalkyl is C3-C10-cycloalkyl and alkynyl is C2-C27-alkynyl; [(C7-C30-arylalkyl)CONH2]CO2B, where aryl is C6-C10-aryl and alkyl is C1-C24-alkyl; [(C7-C30-arylalkenyl)CONH2]CO2B, where aryl is C6-C10-aryl and alkenyl is C2-C24-alkenyl; [(C7-C30-arylalkynyl)CONH2]CO2B, where aryl is C6-C10-aryl and alkynyl is C2-C24-alkynyl; (C1-C30-alkyl-S-A″)CO2B; (C1-C30-alkenyl-S-A″)CO2B; (C1-C30-alkynyl-S-A″)CO2B; (C4-C30-cycloalkylalkyl-S-A″)CO2B, where cycloalkyl is C3-C10-cycloalkyl and alkyl is C1-C27-alkyl; (C4-C30-cycloalkylalkenyl-S-A″)CO2B, where cycloalkyl is C3-C10-cycloalkyl and alkenyl is C2-C27-alkenyl; (C4-C30-cycloalkylalkynyl-S-A″)CO2B, where cycloalkyl is C3-C10-cycloalkyl and alkynyl is C2-C27-alkynyl; (C7-C30-arylalkyl-S-A″)CO2B, where aryl is C6-C10-aryl and alkyl is C1-C24-alkyl; (C8-C30-arylalkenyl-S-A″)CO2B, where aryl is C6-C10-aryl and alkenyl is C2-C24-alkenyl; (C8-C30-arylalkynyl-S-A″)CO2B, where aryl is C6-C10-aryl and alkynyl is C2-C24-alkynyl; wherein B is as defined above and A″ is H; C1-C30-alkyl; C1-C30-alkenyl; C1-C30-alkynyl; C4-C30-cycloalkylalkyl, where cycloalkyl is C3-C10-cycloalkyl and alkyl is C1-C27-alkyl; C4-C30-cycloalkylalkenyl, where cycloalkyl is C3-C10-cycloalkyl and alkenyl is C2-C27-alkenyl; C4-C30-cycloalkylalkynyl, where cycloalkyl is C3-C10-cycloalkyl and alkynyl is C2-C27-alkynyl; C7-C30-arylalkyl, where aryl is C6-C10-aryl and alkyl is C1-C24-alkyl; C8-C30-arylalkenyl, where aryl is C6-C10-aryl and alkenyl is C2-C24-alkenyl; C8-C30-arylalkynyl, where aryl is C6-C10-aryl and alkynyl is C2-C24-alkynyl; n=1-30(CHDCONH)nCHDCO2B, where D is H; C1-C30-alkyl; C1-C30-alkenyl; C1-C30-alkynyl; C4-C30-cycloalkylalkyl, where cycloalkyl is C3-C10-cycloalkyl and alkyl is C1-C27-alkyl; C4-C30-cycloalkylalkenyl, where cycloalkyl is C3-C10-cycloalkyl and alkenyl is C2-C27-alkenyl; C4-C30-cycloalkylalkynyl, where cycloalkyl is C3-C10-cycloalkyl and alkynyl is C2-C27-alkynyl; C7-C30-arylalkyl, where aryl is C6-C10-aryl and alkyl is C1-C24-alkyl; C8-C30-arylalkenyl, where aryl is C6-C10-aryl and alkenyl is C2-C24-alkenyl; C8-C30-arylalkynyl, where aryl is C6-C10-aryl and alkynyl is C2-C24-alkynyl; (C1-C30-alkyl)CO2B; (C1-C30-alkenyl)CO2B; (C1-C30-alkynyl)CO2B; (C4-C30-cycloalkylalkyl)CO2B, where cycloalkyl is C3-C10-cycloalkyl and alkyl is C1-C27-alkyl; (C4-C30-cycloalkylalkenyl)CO2B, where cycloalkyl is C3-C10-cycloalkyl and alkenyl is C2-C27-alkenyl; (C4-C30-cycloalkylalkynyl)CO2B, where cycloalkyl is C3-C10-cycloalkyl and alkynyl is C2-C27-alkynyl; (C7-C30-arylalkyl)CO2B, where aryl is C6-C10-aryl and alkyl is C1-C24-alkyl; (C7-C30-arylalkenyl)CO2B, where aryl is C6-C10-aryl and alkenyl is C2-C24-alkenyl; (C7-C30-arylalkynyl)CO2B, where aryl is C6-C10-aryl and alkynyl is C2-C24-alkynyl;
(C1-C30-alkyl)CONH2; (C1-C30-alkenyl)CONH2; (C1-C30-alkynyl)CONH2; (C4-C30-cycloalkylalkyl)CONH2, where cycloalkyl is C3-C10-cycloalkyl and alkyl is C1-C27-alkyl; (C4-C30-cycloalkylalkenyl)CONH2, where cycloalkyl is C3-C10-cycloalkyl and alkenyl is C2-C27-alkenyl; (C4-C30-cycloalkylalkynyl)CONH2, where cycloalkyl is C3-C10-cycloalkyl and alkynyl is C2-C27-alkynyl; (C7-C30-arylalkyl)CONH2, where aryl is C6-C10-aryl and alkyl is C1-C24-alkyl; (C7-C30-arylalkenyl)CONH2, where aryl is C6-C10-aryl and alkenyl is C2-C24-alkenyl; (C7-C30-arylalkynyl)CONH2, where aryl is C6-C10-aryl and alkynyl is C2-C24-alkynyl; where B is as defined above;
(C1-C30-alkyl)SO3A″; (C1-C30-alkenyl)SO3A″; (C1-C30-alkynyl)SO3A″; (C4-C30-cycloalkylalkyl)SO3A″, where cycloalkyl is C3-C10-cycloalkyl and alkyl is C1-C27-alkyl; (C4-C30-cycloalkylalkenyl)SO3A″, where cycloalkyl is C3-C10-cycloalkyl and alkenyl is C2-C27-alkenyl; (C4-C30-cycloalkylalkynyl)SO3A″, where cycloalkyl is C3-C10-cycloalkyl and alkynyl is C2-C27-alkynyl; (C7-C30-arylalkyl)SO3A″, where aryl is C6-C10-aryl and alkyl is C1-C24-alkyl; (C8-C30-arylalkenyl)SO3A″, where aryl is C6-C10-aryl and alkenyl is C2-C24-alkenyl; (C8-C30-arylalkynyl)SO3A″, where aryl is C6-C10-aryl and alkynyl is C2-C24-alkynyl; (C1-C30-alkyl)PO(OA″)2; (C1-C30-alkenyl)PO(OA″)2; (C1-C30-alkynyl)PO(OA″)2; (C4-C30-cycloalkylalkyl)PO(OA″)2, where cycloalkyl is C3-C10-cycloalkyl and alkyl is C1-C27-alkyl; (C4-C30-cycloalkylalkenyl)PO(OA″)2, where cycloalkyl is C3-C10-cycloalkyl and alkenyl is C2-C27-alkenyl; (C4-C30-cycloalkylalkynyl)PO(OA″)2, where cycloalkyl is C3-C10-cycloalkyl and alkynyl is C2-C27-alkynyl; (C7-C30-arylalkyl)PO(OA″)2, where aryl is C6-C10-aryl and alkyl is C1-C24-alkyl; (C8-C30-arylalkenyl)PO(OA″)2, where aryl is C6-C10-aryl and alkenyl is C2-C24-alkenyl; (C8-C30-arylalkynyl)PO(OA″)2, where aryl is C6-C10-aryl and alkynyl is C2-C24-alkynyl; wherein A″ is H; C1-C30-alkyl; C1-C30-alkenyl; C1-C30-alkynyl; C4-C30-cycloalkylalkyl, where cycloalkyl is C3-C10-cycloalkyl and alkyl is C1-C27-alkyl; C4-C30-cycloalkylalkenyl, where cycloalkyl is C3-C10-cycloalkyl and alkenyl is C2-C27-alkenyl; C4-C30-cycloalkylalkynyl, where cycloalkyl is C3-C10-cycloalkyl and alkynyl is C2-C27-alkynyl; C7-C30-arylalkyl, where aryl is C6-C10-aryl and alkyl is C1-C24-alkyl; C8-C30-arylalkenyl, where aryl is C6-C10-aryl and alkenyl is C2-C24-alkenyl; C8-C30-arylalkynyl, where aryl is C6-C10-aryl and alkynyl is C2-C24-alkynyl;
wherein at least one of R5 and R6 is selected from group (VIIIa);
and pharmaceutically acceptable acid addition salts as well as base addition salts and easily accessible derivatives (e.g. esters or amides of amino acid derivatives), as well as polymorphic forms thereof.

### Claim 20 (depends on 19)

Compounds according to claim 19, wherein one of R5 and R6 is selected from group (VIIIa) and the other one represents H or OH.

### Claim 21 (depends on 19)

Compounds according to claim 19, wherein X is oxygen.

### Claim 22 (depends on 19)

Compounds according to claim 19, wherein the compound is present as base addition salt.

### Claim 23 (depends on 22)

Compounds according to claim 22, wherein the base addition salt is selected among lithium salts, sodium salts, potassium salts, beryllium salts, magnesium salts, calcium salts, strontium salts, aluminum salts and zinc salts, C1-C30 monoalkylammonium salts, C1-C30 dialkylammonium salts, C1-C30 trialkylammonium salts, C1-C30 tetraalkylammonium salts; C2-C30 monoalkenylammonium salts, C2-C30 dialkenylammonium salts, C2-C30 trialkenylammonium salts, C2-C30 tetraalkenylammonium salts; C2-C30 monoalkynylammonium salts, C2-C30 dialkynylammonium salts, C2-C30 trialkynylammonium salts, C2-C30 tetraalkynylammonium salts; C4-C30 mono(cyclo alkylalkylammonium) salts, C4-C30 di(cycloalkylalkylammonium) salts, C4-C30 tri(cycloalkylalkylammonium) salts, C4-C30 tetra(cycloalkylalkylammonium) salts, where cycloalkyl is C3-C10-cycloalkyl and alkyl is C1-C27-alkyl; C5-C30 mono(cycloalkylalkenylammonium) salts, C5-C30 di(cycloalkylalkenylammonium) salts, C5-C30 tri(cycloalkylalkenylammonium) salts, C5-C30 tetra(cycloalkylalkenylammonium) salts, where cycloalkyl is C3-C10-cycloalkyl and alkenyl is C2-C27-alkenyl; C5-C30 mono(cycloalkylalkynylammonium) salts, C5-C30 di(cycloalkylalkynylammonium) salts, C5-C30 tri(cycloalkylalkynylammonium) salts, C5-C30 tetra(cycloalkylalkynylammonium) salts, where cycloalkyl is C3-C10-cycloalkyl and alkynyl is C2-C27-alkynyl; C7-C30 mono(arylalkylammonium) salts, C7-C30 di(arylalkylammonium) salts, C7-C30 tri(arylalkylammonium) salts, C7-C30 tetra(arylalkylammonium) salts, where aryl is C6-C10-aryl and alkyl is C1-C24-alkyl; C8-C30 mono(arylalkenylammonium) salts, C8-C30 di(arylalkenylammonium) salts, C8-C30 tri(arylalkenylammonium) salts, C8-C30 tetra(arylalkenylammonium) salts, where aryl is C6-C10-aryl and alkenyl is C2-C24-alkenyl; C8-C30 mono(arylalkynylammonium) salts, C8-C30 di(arylalkynylammonium) salts, C8-C30 tri(arylalkynylammonium) salts, C8-C30 tetra(arylalkynylammonium) salts, where aryl is C6-C10-aryl and alkynyl is C2-C24-alkynyl, combinations of the ammonium salts listed above, and salts derived from heterocyclic nitrogen bases.

### Claim 24 (depends on 19)

Compounds according to claim 19 as medicament.

### Claim 25 (depends on 19)

Use of a compound of claim 19 for the manufacture of a medicament for the treatment of pain.

### Claim 26 (depends on 19)

Use of a compound of claim 19 for the manufacture of a medicament for the treatment of intestinal diseases, in particular chronic inflammation of the small and large intestines (irritable colon syndrome—colon irritabile, colitis ulcerosa, morbus Crohn), diarrhoea or obstipation.

### Claim 27 (depends on 19)

Use of a compound of claim 19 for the manufacture of a medicament for the treatment of rheumatic diseases, including rheumatoid arthritis, osteoarthritis, arthrosis, spondylosis, lumbago, lupus erythematosus, spondylarthropathy.

### Claim 28 (depends on 19)

Use of a compound of claim 19 for the manufacture of a medicament for the treatment of tumours and cancer as well as for the treatment of obesity and overweight, and also for the suppression of rejection of transplants after transplantations and for the prevention and treatment of intestinal obstruction (ileus).

### Claim 29 (depends on 19)

Use of a compound of claim 19 for the manufacture of a medicament for the withdrawal from drug addiction, for example, to opiates, cocaine or alcohol and for the treatment of psychic diseases.

### Claim 30 (depends on 1)

Compounds of claim 1, wherein the polymorphic form is a crystalline polymorphic form.

### Claim 31 (depends on 1)

Compounds of claim 1, wherein the polymorphic form is an amorphous polymorphic form.

### Claim 32 (depends on 4, 5)

Method for synthesizing a compound according to claim 5, comprising the following reaction sequence:
wherein R1 to R4 are as defined in claim 4 and R7 and R8 are selected so that compound (VII) is in accordance with the definitions for R5 and R6 as given in claim 4 and R9 is selected from any suitably organic moiety not detrimental for the reaction.
